$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
Frank Vinluan / medcitynews - GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First…
AI Summary: GSK has won FDA approval for its first lung cancer drug, a gene-targeting therapy that validates the company’s heavy investment and recent M&A strategy. The approval follows pivotal trial evidence of clinical benefit and positions GSK competitively in thoracic oncology, offering a new therapeutic choice for patients with the relevant molecular profile.
Related Stories
FDA approves Replimune’s Tudriqev after repeated rejections / 4 wks
FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 3 months
FDA to revisit Atara/Pierre Fabre cell therapy approval for rare lymphoma / 3 months
FDA advisory panel rejects camizestrant after SERENA‑6 results / 4 months
Decade-Long Persistence of CD19 CAR‑T Cells in B‑Cell Lymphomas / 23 days
Bristol Myers Squibb wins first-in-class approval for protein‑degrader myeloma therapy / 24 days
Belzutifan plus pembrolizumab gains approval for adjuvant RCC / 6 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pharmaceuticals, Hearing Loss, Infant Health, Hospital Operations and look for the RSS link.
StackHealth Time Machine